CGON Stock Price | CG Oncology, Inc. Common stock P/E, Revenue, EPS, & Forecasts

CG Oncology, Inc. Common stock • CGON

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About CG Oncology, Inc. Common stock

Ticker

CGON

Trading on

NASDAQ

ISIN

US1569441009

Industry

Biotechnology

Sector

Healthcare

CEO

Arthur Kuan

Headquarters

400 Spectrum Center Drive, Irvine, CA, United States, 92618

Employees

113

Website

https://cgoncology.com

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003, which is in phase 3 clinical trial for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 that is in phase 2 clinical trial to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy that is in phase 3 clinical trial for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008, which is in phase 2 clinical trial for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.

Metrics

BasicAdvanced

Market cap

$1.84B

P/E ratio

EPS

-$1.41

Dividend Yield

0.00%

Beta

Forward P/E ratio

EBIDTA

$-134M

Ex dividend date

Price & volume

Market cap

$1.84B

Average daily volume

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

2,784.06

Price to book

2.51

Earnings

EPS

-$1.41

EPS estimate (current quarter)

-$0.46

EPS estimate (next quarter)

-$0.38

EBITDA

$-134M

Revenues (TTM)

$0.7M

Revenues per share (TTM)

$0.01

Technicals

Beta

52-week High

$40.47

52-week Low

$14.80

50-day moving average

$23.97

200-day moving average

$30.85

Short ratio

5.94

Short %

15.59%

Management effectiveness

ROE (TTM)

16.58%

ROA (TTM)

12.85%

Profit margin

0.00%

Gross profit margin

$-91.7M

Operating margin

81,161.54%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

90.20%

Share stats

Outstanding Shares

76.2M

Float

61.1M

Insiders %

1.17%

Institutions %

98.66%

Analyst Insights & forecasts

90% Buy

10% Hold

0% Sell

Based on information from 10 analysts.

Average price target

$60.22

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.36

-$0.29

24.14%

Q1 • 24Beat

-$0.28

-$0.32

11.11%

Q2 • 24Beat

-$0.30

-$0.34

11.92%

Q3 • 24Beat

-$0.48

-$0.46

4.35%

Q4 • 24Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0M

$-20.4M

47,453.49%

Q3 • 24

$0.5M

$-31.8M

6,973.25%

Q4 • 24

960.47%

55.83%

85.31%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$552M

$15.7M

2.84%

Q3 • 24

$755M

$21.4M

2.84%

Q4 • 24

36.62%

36.42%

0.14%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-15.9M

$32M

$2.2M

$-15.9M

Q3 • 24

$-20.7M

$10.9M

$223M

$-20.9M

Q4 • 24

29.79%

65.93%

10,209.83%

31.12%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a CG Oncology, Inc. Common stock share?

CG Oncology, Inc. Common stock shares are currently traded for undefined per share.

How many shares does CG Oncology, Inc. Common stock have?

CG Oncology, Inc. Common stock currently has 76.2M shares.

Does CG Oncology, Inc. Common stock pay dividends?

No, CG Oncology, Inc. Common stock doesn't pay dividends.

What is CG Oncology, Inc. Common stock 52 week high?

CG Oncology, Inc. Common stock 52 week high is $40.47.

What is CG Oncology, Inc. Common stock 52 week low?

CG Oncology, Inc. Common stock 52 week low is $14.80.

What is the 200-day moving average of CG Oncology, Inc. Common stock?

CG Oncology, Inc. Common stock 200-day moving average is $30.85.

Who is CG Oncology, Inc. Common stock CEO?

The CEO of CG Oncology, Inc. Common stock is Arthur Kuan.

How many employees CG Oncology, Inc. Common stock has?

CG Oncology, Inc. Common stock has 113 employees.

What is the market cap of CG Oncology, Inc. Common stock?

The market cap of CG Oncology, Inc. Common stock is $1.84B.

What is the P/E of CG Oncology, Inc. Common stock?

The current P/E of CG Oncology, Inc. Common stock is null.

What is the EPS of CG Oncology, Inc. Common stock?

The EPS of CG Oncology, Inc. Common stock is -$1.41.

What is the PEG Ratio of CG Oncology, Inc. Common stock?

The PEG Ratio of CG Oncology, Inc. Common stock is null.

What do analysts say about CG Oncology, Inc. Common stock?

According to the analysts CG Oncology, Inc. Common stock is considered a buy.